A systematic analysis of the resistance and sensitivity of HER2^YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer

References

• Esposito L, Conti D, Ailavajhala R, et al. Lung cancer: are we up to the challenge? Curr Genom 2010;11:513–18
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, Barni S. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 2012;13:107–14
   PubMed Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734–9
   PubMed Web of Science ®Google Scholar
• Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005;353:1652–4
   PubMed Web of Science ®Google Scholar
• Heinmöller P, Gross C, Beyser K, et al. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res 2003;9:5238–43
   PubMed Web of Science ®Google Scholar
• Garrido-Castro AC, Felip E. HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. Transl Lung Cancer Res 2013;2:122–7
   PubMedGoogle Scholar
• Li C, Sun Y, Fang R, et al. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains. J Thorac Oncol 2012;7:85–9
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65:1642–6
   PubMed Web of Science ®Google Scholar
• Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006;10:25–38
   PubMed Web of Science ®Google Scholar
• Perera SA, Li D, Shimamura T, et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci USA 2009;106:474–9
   PubMed Web of Science ®Google Scholar
• Telesco SE, Shih A, Liu Y, Radhakrishnan R. Investigating molecular mechanisms of activation and mutation of the HER2 receptor tyrosine kinase through computational modeling and simulation. Cancer Res J 2011;4:1–35
   PubMedGoogle Scholar
• Yang B, Zhang H, Wang H. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study. J Mol Model 2015;21:24–36
   PubMed Web of Science ®Google Scholar
• Burris HA. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004;9:10–15
   PubMed Web of Science ®Google Scholar
• Doi T, Takiuchi H, Ohtsu A, et al. Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. Br J Cancer 2012;106:666–72
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235–42
   PubMed Web of Science ®Google Scholar
• Uniprot C. Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res 2010;39:D214–19
   PubMed Web of Science ®Google Scholar
• Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673–80
   PubMed Web of Science ®Google Scholar
• Fiser A, Sali A. Modeller: generation and refinement of homology-based protein structure models. Meth Enzymol 2003;374:461–91
   PubMed Web of Science ®Google Scholar
• Wang B, Shen W, Yang H, et al. Targeting EGFR mutants with non-cognate kinase inhibitors in non-small cell lung cancer. Med Chem Res 2014;23:4510–30
   Web of Science ®Google Scholar
• Case DA, Cheatham TE, Darden T, et al. The Amber biomolecular simulation programs. J Comput Chem 2005;26:1668–88
   PubMed Web of Science ®Google Scholar
• Jorgensen WL, Chandrasekhar J, Madura JD, et al. Comparison of simple potential functions for simulating liquid water. J Phys Chem 1983;79:926–35
   Web of Science ®Google Scholar
• Darden T, York D, Pedersen L. Particle mesh Ewald: and N.log(N) method for Ewald sums in large systems. J Chem Phys 1993;98:10089–92
   Web of Science ®Google Scholar
• Ryckaert J, Ciccotti G, Berendsen HJC. Numerical-integration of Cartesian equations of motion of a system with constraints – molecular-dynamics of n-alkanes. J Comput Phys 1977;23:327–41
   Web of Science ®Google Scholar
• Wang J, Wolf RM, Caldwell JW, et al. Development and testing of a general amber force field. J Comput Chem 2004;25:1157–74
   PubMed Web of Science ®Google Scholar
• Kollman PA, Massova I, Reyes C, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 2000;33:889–97
   PubMed Web of Science ®Google Scholar
• Ai X, Sun Y, Wang H, Lu S. A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity. Amino Acids 2014;46:1635–48
   PubMed Web of Science ®Google Scholar
• Aertgeerts K, Skene R, Yano J, et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem 2011;286:18756–65
   PubMed Web of Science ®Google Scholar
• Stasi I, Cappuzzo F. Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer. Transl Resp Med 2014;2:2–9
   PubMedGoogle Scholar
• Quintás-Cardama A, Kantarjian H, Cortes J. Third-generation tyrosine kinase inhibitors and beyond. Semin Hematol 2010;47:371–80
   PubMed Web of Science ®Google Scholar
• De Grève J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012;76:123–7
   PubMed Web of Science ®Google Scholar
• Kim HP, Han SW, Kim SH, et al. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol Cancer Ther 2008;7:607–15
   PubMed Web of Science ®Google Scholar
• Gilmer TM, Cable L, Alligood K, et al. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer Res 2008;68:571–9
   PubMed Web of Science ®Google Scholar
• Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein–ligand interactions. Protein Eng 1995;8:127–34
   PubMedGoogle Scholar